Rhumbline Advisers Buys 1,042 Shares of OrthoPediatrics Corp. (NASDAQ:KIDS)

Rhumbline Advisers raised its stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) by 4.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 26,411 shares of the company’s stock after buying an additional 1,042 shares during the period. Rhumbline Advisers owned about 0.11% of OrthoPediatrics worth $612,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of KIDS. Quarry LP bought a new position in OrthoPediatrics in the third quarter worth approximately $25,000. International Assets Investment Management LLC increased its stake in shares of OrthoPediatrics by 2,610.8% in the 3rd quarter. International Assets Investment Management LLC now owns 1,003 shares of the company’s stock worth $27,000 after purchasing an additional 966 shares in the last quarter. Creative Planning increased its stake in shares of OrthoPediatrics by 15.4% in the 3rd quarter. Creative Planning now owns 10,130 shares of the company’s stock worth $275,000 after purchasing an additional 1,353 shares in the last quarter. Quantbot Technologies LP raised its holdings in OrthoPediatrics by 42.2% in the 3rd quarter. Quantbot Technologies LP now owns 5,773 shares of the company’s stock worth $157,000 after purchasing an additional 1,712 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in OrthoPediatrics by 125.1% during the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock valued at $94,000 after purchasing an additional 1,929 shares in the last quarter. 69.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on KIDS shares. Stifel Nicolaus reduced their price target on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $42.00 target price on shares of OrthoPediatrics in a report on Wednesday. Finally, Truist Financial lowered their price target on shares of OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th.

OrthoPediatrics Stock Performance

NASDAQ KIDS opened at $25.35 on Friday. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19. OrthoPediatrics Corp. has a twelve month low of $21.02 and a twelve month high of $35.99. The business has a 50-day moving average price of $24.48 and a 200-day moving average price of $25.93. The firm has a market cap of $613.88 million, a price-to-earnings ratio of -20.61 and a beta of 1.14.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The business had revenue of $52.67 million during the quarter, compared to the consensus estimate of $51.16 million. During the same period in the prior year, the company posted ($0.23) EPS. As a group, equities research analysts predict that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.